Silence Therapeutics Plc: 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silence Therapeutics Plc on August 10, 2026. The filing discloses positive topline results from the Phase 2 SANRECO trial evaluating the investigational drug divesiran for the treatment of polycythemia vera (PV).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial outcomes and forward-looking development plans.
Material Changes and Clinical Results
The primary material change is the successful completion of the Phase 2 SANRECO trial, a 36-week, randomized, double-blind, placebo-controlled study. Key findings include:
- Primary Endpoint: Met with statistical significance (p<0.0001). 88% of divesiran-treated patients achieved a clinical response (absence of phlebotomy and hematocrit <45% during weeks 18-36) compared to 19% in the placebo group.
- Dose Efficacy: Response rates were 93.8% for the every-six-weeks (Q6W) dose and 81.3% for the every-twelve-weeks (Q12W) dose.
- Secondary Endpoint: Met with a significant reduction in phlebotomy rates (0.2 per patient for divesiran vs. 2.1 for placebo).
- Additional Benefits: Improvements observed in hematocrit control, iron markers (ferritin), and patient-reported outcomes (MPN-SAF TSS).
- Safety: Divesiran was well-tolerated with no new safety findings. Injection site reactions were infrequent. Two cases of grade 1 anemia were reported.
Guidance, Outlook, and Risks
Based on these results, management expects to initiate a Phase 3 trial evaluating divesiran with Q12W dosing versus placebo in the first half of 2027. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks detailed in the Company's Form 10-K for the year ended December 31, 2025.
Investor Verification Checklist
- Verify the specific statistical data and patient demographics in the full press release (Exhibit 99.1) and conference call presentation (Exhibit 99.2).
- Confirm the regulatory pathway and specific endpoints for the planned Phase 3 trial to be initiated in 2027.
- Review the Company's cash runway and capital requirements to fund the upcoming Phase 3 trial, as this filing does not disclose current liquidity.
- Assess the competitive landscape for polycythemia vera treatments in light of the 81.3% response rate for the Q12W dosing regimen.